Skip to main content
RENERVE LIMITED logo

RENERVE LIMITED — Investor Relations & Filings

Ticker · RNV ISIN · AU0000358616 ASX Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-09-21 Investor Presentation
Country AU Australia
Listing ASX RNV

About RENERVE LIMITED

https://renerve.com.au/

Renerve Limited is a medical technology company focused on the development and commercialization of advanced solutions for tissue repair and regeneration. The company specializes in peripheral nerve repair through its proprietary NervAlign platform. This technology utilizes a specialized decellularization process to create high-quality nerve grafts derived from porcine tissue. These grafts are designed to provide a natural scaffold that supports and guides axonal regrowth across nerve gaps, offering an alternative to traditional autografts. By maintaining the structural integrity and biochemical cues of the extracellular matrix, Renerve's products aim to improve functional recovery outcomes for patients suffering from traumatic nerve injuries. The company's research and development efforts are centered on expanding the applications of its tissue engineering platform to address various clinical needs in regenerative medicine.

Recent filings

Filing Released Lang Actions
Empliq Product Launch 13 pages 1.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about the launch of a new product range by ReNerve Ltd, including marketing updates, product descriptions, market analysis, and launch plans. It contains no financial statements, regulatory filings, voting results, or management changes. The content is focused on informing investors and stakeholders about the company's product strategy and market positioning. The presence of slides, disclaimers, and forward-looking statements typical of investor communications further supports this. Therefore, this document fits the category of an Investor Presentation (IP).
2025-09-21 English
Application for quotation of securities - RNV 8 pages 20.8KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement by RENERVE LIMITED regarding the application for quotation of newly issued securities on the ASX. It details the number and type of securities to be quoted, issue dates, distribution schedules, and issued capital following quotation. The document references previous announcements (Appendix 3B) related to the securities issuance. This type of document is a formal application to list or quote securities on the exchange, which corresponds to announcements about share issues or capital changes. It is not a financial report, earnings release, or management discussion. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is over 6000 characters and contains detailed information, not just a brief announcement or link to a report, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high due to clear identification of the document type and content.
2025-09-16 English
Cleansing Notice 3 pages 224.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 17 September 2025 by ReNerve Limited. It is a notice under section 708A(5)(e) of the Corporations Act 2001 (Cth), which relates to the issuance of new shares without disclosure under Part 6D.2 of the Act. The announcement details the issuance of 600,000 fully paid ordinary shares at $0.10 per share and confirms compliance with relevant sections of the Act. The document is short (4237 characters) and primarily serves as a regulatory notice about a capital raising event. It does not contain financial statements or detailed financial analysis but is an update on a financing activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-09-16 English
Proposed issue of securities - RNV 5 pages 17.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed placement or other type of securities issue by RENERVE LIMITED. It includes specifics such as the number of securities to be issued, the issue date, and compliance with ASX Listing Rules. The content focuses on the announcement of a new securities issue rather than a financial report or earnings release. There is no financial statement or management discussion, nor is it a report publication or certification. This matches the definition of a Share Issue/Capital Change announcement.
2025-09-15 English
ReNerve - Appendix 4E 2 pages 122.8KB
Earnings Release Classification · 95% confidence The document is titled 'ReNerve Limited Appendix 4E Preliminary final report' and covers the financial year ended 30 June 2025. It includes key financial results such as loss after tax, net tangible assets, and audit opinion. The document states that the Annual Report for the year ended 30 June 2025 is attached, indicating this document is a preliminary final report rather than the full Annual Report itself. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are announcements of full year results but not the full detailed Annual Report. The document length is 2060 characters, which is relatively short and consistent with a preliminary announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER) since it announces the full year financial results with key highlights but is not the full Annual Report (10-K).
2025-08-28 English
ReNerve 2025 Annual Report 51 pages 1.5MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2025' and includes detailed sections typical of an annual report such as Chairman's Letter, Directors' Report, Auditors' Independent Declaration, and full financial statements (Statement of Profit or Loss, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flows). It covers the fiscal year ended 30 June 2025 and contains comprehensive information about company operations, financial performance, governance, and strategic initiatives. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the full annual report, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K).
2025-08-28 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.